HSP90AA1 and early-onset autosomal dominant Alzheimer disease: In recent years, numerous network pharmacology studies have identified HSP90AA1 as a key target of various natural products and traditional Chinese medicine (TCM) formulations that have been used for the treatment of a range of diseases, including Alzheimer’s disease [75], metabolic syndrome [76], and myocardial ischemia–reperfusion injury [77].